Financhill
Sell
11

DVAX Quote, Financials, Valuation and Earnings

Last price:
$10.30
Seasonality move :
13.47%
Day range:
$10.26 - $10.79
52-week range:
$9.74 - $14.63
Dividend yield:
0%
P/E ratio:
57.28x
P/S ratio:
5.32x
P/B ratio:
2.14x
Volume:
3M
Avg. volume:
2.6M
1-year change:
-9.8%
Market cap:
$1.3B
Revenue:
$277.2M
EPS (TTM):
$0.18

Analysts' Opinion

  • Consensus Rating
    Dynavax Technologies has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $24.25, Dynavax Technologies has an estimated upside of 135.21% from its current price of $10.31.
  • Price Target Downside
    According to analysts, the lowest downside price target is $10.00 representing -- downside risk from its current price of $10.31.

Fair Value

  • According to the consensus of 2 analysts, Dynavax Technologies has 135.21% upside to fair value with a price target of $24.25 per share.

DVAX vs. S&P 500

  • Over the past 5 trading days, Dynavax Technologies has overperformed the S&P 500 by 1.53% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Dynavax Technologies does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Dynavax Technologies has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Dynavax Technologies reported revenues of $72M.

Earnings Growth

  • Dynavax Technologies has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Dynavax Technologies reported earnings per share of $0.05.
Enterprise value:
789.2M
EV / Invested capital:
--
Price / LTM sales:
5.32x
EV / EBIT:
20.96x
EV / Revenue:
2.85x
PEG ratio (5yr expected):
--
EV / Free cash flow:
13.12x
Price / Operating cash flow:
24.50x
Enterprise value / EBITDA:
17.27x
Gross Profit (TTM):
$227.8M
Return On Assets:
2.71%
Net Income Margin (TTM):
9.85%
Return On Equity:
4.32%
Return On Invested Capital:
3.19%
Operating Margin:
-2.27%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $722.7M $232.3M $277.2M $55.6M $72M
Gross Profit $460.5M $182.1M $227.8M $46.9M $58.6M
Operating Income $282.5M -$25.7M -$4.1M -$8.5M -$1.6M
EBITDA $308M $9.7M $45.7M $5.5M $12.3M
Diluted EPS $1.97 -$0.06 $0.18 -- $0.05
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $290M $972.5M $917M $859.1M $848.9M
Total Assets $353.3M $1B $985.9M $997.1M $986.3M
Current Liabilities $77.4M $556.4M $150.1M $62.2M $78.6M
Total Liabilities $294.6M $816.9M $404.8M $375M $389.5M
Total Equity $58.7M $222.4M $581M $622.1M $596.8M
Total Debt $179.8M $220.5M $221.6M $222.7M $223.9M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $62.7M $100.6M $66.5M $13.8M $53M
Cash From Investing -$316M -$153.9M -$18M -$20.2M $23.4M
Cash From Financing $19.5M $1.4M -$102M $1.8M -$98.9M
Free Cash Flow $55.6M $96.5M $60.2M $12M $49.5M
DVAX
Sector
Market Cap
$1.3B
$35M
Price % of 52-Week High
--
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-9.8%
-41.61%
Beta (5-Year)
1.265
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $11.23
200-day SMA
Sell
Level $12.05
Bollinger Bands (100)
Sell
Level 12.2 - 13.6
Chaikin Money Flow
Sell
Level -5.8M
20-day SMA
Sell
Level $12.45
Relative Strength Index (RSI14)
Sell
Level 24.20
ADX Line
Sell
Level 53.33
Williams %R
Buy
Level -98.2813
50-day SMA
Sell
Level $13.05
MACD (12, 26)
Buy
Level 1.56
25-day Aroon Oscillator
Sell
Level -64
On Balance Volume
Sell
Level -11.3M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.5302)
Buy
CA Score (Annual)
Level (0.3412)
Buy
Beneish M-Score (Annual)
Level (-2.5958)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.9635)
Buy
Piotroski F Score (Annual)
Level (8)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Stock Forecast FAQ

In the current month, DVAX has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DVAX average analyst price target in the past 3 months is $24.25.

  • Where Will Dynavax Technologies Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Dynavax Technologies share price will rise to $24.25 per share over the next 12 months.

  • What Do Analysts Say About Dynavax Technologies?

    Analysts are divided on their view about Dynavax Technologies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dynavax Technologies is a Sell and believe this share price will drop from its current level to $10.00.

  • What Is Dynavax Technologies's Price Target?

    The price target for Dynavax Technologies over the next 1-year time period is forecast to be $24.25 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is DVAX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Dynavax Technologies is a Buy. 2 of 2 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of DVAX?

    You can purchase shares of Dynavax Technologies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dynavax Technologies shares.

  • What Is The Dynavax Technologies Share Price Today?

    Dynavax Technologies was last trading at $10.30 per share. This represents the most recent stock quote for Dynavax Technologies. Yesterday, Dynavax Technologies closed at $10.31 per share.

  • How To Buy Dynavax Technologies Stock Online?

    In order to purchase Dynavax Technologies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Can Spotify Ever Become Consistently Profitable?
Can Spotify Ever Become Consistently Profitable?

Spotify (NYSE:SPOT) owns more than 30% market share as the most…

Is American Express a Buy, Sell or Hold?
Is American Express a Buy, Sell or Hold?

American Express (NYSE:AXP) holds a notable place in Warren Buffett’s…

Is Baidu Stock a Sleeper AI Winner?
Is Baidu Stock a Sleeper AI Winner?

Although the recent policy decisions have gripped the market now,…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 32x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 31x

Sell
46
Is NVDA Stock a Buy?

Market Cap: $2.5T
P/E Ratio: 35x

Alerts

Sell
23
UNH alert for Apr 20

UnitedHealth Group [UNH] is down 22.4% over the past day.

Sell
32
MAN alert for Apr 20

ManpowerGroup [MAN] is down 19.07% over the past day.

Sell
24
GPN alert for Apr 20

Global Payments [GPN] is down 17.44% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock